Persistence and Compliance with Pazopanib in Patients with Advanced Renal Cell Carcinoma Within a U.S. Administrative Claims Database

BACKGROUND: Pazopanib is an oral tyrosine kinase inhibitor with demonstrated efficacy and tolerability in patients with advanced renal cell carcinoma (RCC). OBJECTIVES: To examine pazopanib persistence and compliance (adherence) and other drug utilization patterns in both treatment-naïve (first-line...

Descripción completa

Detalles Bibliográficos
Autores principales: Hackshaw, Michelle D., Nagar, Saurabh P., Parks, Daniel C., Miller, Lesley-Ann N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438225/
https://www.ncbi.nlm.nih.gov/pubmed/24856598
http://dx.doi.org/10.18553/jmcp.2014.20.6.603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438225/
https://www.ncbi.nlm.nih.gov/pubmed/24856598
http://dx.doi.org/10.18553/jmcp.2014.20.6.603

Ejemplares similares